Patients with relapsed/refractory mantle cell lymphoma respond to CAR T-cell therapy
Click Here to Manage Email Alerts
ORLANDO — In a video interview at ASH Annual Meeting and Exposition, Michael L. Wang, MD, professor of lymphoma/myeloma at The Texas University MD Anderson Cancer Center, discussed exciting results from a CAR T-cell therapy study in relapsed/refractory mantle cell lymphoma.
Wang reported that the response rate was over 80% and complete response rate was 53% in 28 patents with R/R mantle cell lymphoma.
“In my option, in the future, we will be able to cure some patients with a cell therapy. There has never been such an exciting time for hematology/oncology and our patients are the luckiest, blessed people. Those with mantle cell lymphoma learn from us that we do have options that will keep them alive for years to come,” he said.
Disclosures: Wang reports research funding from Acerta Pharma, AstraZeneca, Aviara, BioInvent, Celgene, Janssen, Juno Therapeutics, Kite Pharma, Loxo Oncology, Pharmacyclics and VelosBio; honoraria from AstraZeneca, Celgene, Dava Oncology, Janssen and Pharmacyclics; consulting for Acerta Pharma, AstraZeneca, BioInvent, Guidepoint Global, Janssen, Kite Pharma and MoreHealth; equity ownership of MoreHealth; and being on the speakers bureau for AstraZeneca and Janssen.